drug · small molecule
danicamtiv
Phase 3updated 3mo agoby Bristol-Myers Squibb Co🔗 ChEMBL
Phase 3community read0 votes
Small molecule drug with a maximum clinical stage of Phase 2 3 (across all indications), with 2 investigational indications.
targets
Cardiac myosin
all catalysts(0)
nothing on the calendar yet
Trials studying danicamtiv
- phase3A Study of the Efficacy and Safety of Danicamtiv in Participants With Symptomatic Genetic and Familial Dilated Cardiomyopathy
- phase2Exploratory Study of Danicamtiv in Patients With Primary Dilated Cardiomyopathy (DCM) Due to Genetic Variants or Other Causalities
- phase1A Study to Evaluate the Safety, Tolerability, and Drug Levels of Danicamtiv in Healthy Japanese and Caucasian Participants
- phase1A Study to Assess the Effect of Danicamtiv on the Drug Levels of Midazolam in Participants With Stable Heart Failure
- phase1A Study to Assess the Relative Biological Availability and the Effect of Food on the Drug Levels of Danicamtiv in Healthy Adult Participants
News(3)
- 5 NextGen winners who went public this year (and which ones are hiring)BioSpace NextGen honorees made up one-third of the U.S. biotechs that have publicly debuted in 2026. Most are looking for biopharma professionals to join their teams.biospace · 6d ago
- Scribe reels in nearly $129M in rare early-stage IPO for a gene editing biotechJennifer Doudna–founded Scribe Therapeutics intends to use the proceeds from the public offering—the first for a gene editing outfit in over two years—to support development of its epigenetic silen…biospace · 18d ago
- Kardigan extends biotech’s streak of big IPOs with $400M haulIncluding the heart drug developer’s offering, four biotechs in 2026 have raised at least $400 million in IPO proceeds — the most in a single year since 2021, according to BioPharma Dive data.biopharma_dive · 1mo ago
Data sources
last refreshed 21m ago
Found something off?
comments(0)
5-min edit window · permanent after that